A long‐term follow‐up study of cinnarizine‐ and flunarizine‐induced parkinsonism
Identifieur interne : 005425 ( Main/Exploration ); précédent : 005424; suivant : 005426A long‐term follow‐up study of cinnarizine‐ and flunarizine‐induced parkinsonism
Auteurs : A. Negrotti [Italie] ; Calzetti [Italie]Source :
- Movement Disorders [ 0885-3185 ] ; 1997-01.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Aged, Antagonist, Antiallergic, Anticonvulsant, Antiemetic, Antihistaminic, Calcium Channel Blockers (administration & dosage), Calcium Channel Blockers (adverse effects), Calcium antagonist, Cardiovascular Diseases (drug therapy), Cinnarizine, Cinnarizine (administration & dosage), Cinnarizine (adverse effects), Dose-Response Relationship, Drug, Drug‐induced, Elderly, Female, Flunarizine, Flunarizine (administration & dosage), Flunarizine (adverse effects), Follow up study, Follow-Up Studies, H1 receptor, Humans, Long term, Long‐term outcome, Male, Middle Aged, Neurologic Examination (drug effects), Parkinson Disease, Secondary (chemically induced), Parkinson Disease, Secondary (diagnosis), Parkinsonism, Piperazine derivatives, Prognosis, Toxicity, Treatment Outcome, Vasodilator agent.
- MESH :
- chemical , administration & dosage : Calcium Channel Blockers, Cinnarizine, Flunarizine.
- chemical , adverse effects : Calcium Channel Blockers, Cinnarizine, Flunarizine.
- chemically induced : Parkinson Disease, Secondary.
- diagnosis : Parkinson Disease, Secondary.
- drug effects : Neurologic Examination.
- drug therapy : Cardiovascular Diseases.
- Aged, Dose-Response Relationship, Drug, Female, Follow-Up Studies, Humans, Male, Middle Aged, Treatment Outcome.
Abstract
The natural course of calcium‐entry blocker–induced parkinsonism was evaluated in 13 elderly patients previously exposed to cinnarizine or flunarizine or both for a median period of 7 months. Clinical assessments were carried out before drug discontinuation and twice thereafter over a period lasting ≤7 years. None of the patients showed a full recovery of extrapyramidal signs, indicating that the long‐term prognosis of the parkinsonism is less benign than previously reported. Two main patterns of clinical outcome were recognized (i.e., “remittent” and “persistent and not progressive”parkinsonism), whereas the development of a progressive disorder was observed only in one patient. No significant correlation was found between the patterns of outcome and some clinical variables, such as total duration of exposure to cinnarizine and flunarizine, cumulative drug dosages, and age at onset of parkinsonism. There was no significant difference in terms of family history of essential tremor or parkinsonism or both among the patients with the two main patterns of clinical course.
Url:
DOI: 10.1002/mds.870120119
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002D67
- to stream Istex, to step Curation: 002D67
- to stream Istex, to step Checkpoint: 003A49
- to stream PubMed, to step Corpus: 004723
- to stream PubMed, to step Curation: 004723
- to stream PubMed, to step Checkpoint: 004730
- to stream Ncbi, to step Merge: 004C60
- to stream Ncbi, to step Curation: 004C60
- to stream Ncbi, to step Checkpoint: 004C60
- to stream Main, to step Merge: 008454
- to stream PascalFrancis, to step Corpus: 003292
- to stream PascalFrancis, to step Curation: 003532
- to stream PascalFrancis, to step Checkpoint: 003291
- to stream Main, to step Merge: 008646
- to stream Main, to step Curation: 005425
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A long‐term follow‐up study of cinnarizine‐ and flunarizine‐induced parkinsonism</title>
<author><name sortKey="Negrotti, A" sort="Negrotti, A" uniqKey="Negrotti A" first="A." last="Negrotti">A. Negrotti</name>
</author>
<author><name sortKey="Calzetti" sort="Calzetti" uniqKey="Calzetti" last="Calzetti">Calzetti</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:B76868CF03D01070A891C66A47A9A4CDFAF31704</idno>
<date when="1997" year="1997">1997</date>
<idno type="doi">10.1002/mds.870120119</idno>
<idno type="url">https://api.istex.fr/document/B76868CF03D01070A891C66A47A9A4CDFAF31704/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002D67</idno>
<idno type="wicri:Area/Istex/Curation">002D67</idno>
<idno type="wicri:Area/Istex/Checkpoint">003A49</idno>
<idno type="wicri:doubleKey">0885-3185:1997:Negrotti A:a:long:term</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:8990063</idno>
<idno type="wicri:Area/PubMed/Corpus">004723</idno>
<idno type="wicri:Area/PubMed/Curation">004723</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004730</idno>
<idno type="wicri:Area/Ncbi/Merge">004C60</idno>
<idno type="wicri:Area/Ncbi/Curation">004C60</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004C60</idno>
<idno type="wicri:doubleKey">0885-3185:1997:Negrotti A:a:long:term</idno>
<idno type="wicri:Area/Main/Merge">008454</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:97-0142930</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003292</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003532</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">003291</idno>
<idno type="wicri:doubleKey">0885-3185:1997:Negrotti A:a:long:term</idno>
<idno type="wicri:Area/Main/Merge">008646</idno>
<idno type="wicri:Area/Main/Curation">005425</idno>
<idno type="wicri:Area/Main/Exploration">005425</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A long‐term follow‐up study of cinnarizine‐ and flunarizine‐induced parkinsonism</title>
<author><name sortKey="Negrotti, A" sort="Negrotti, A" uniqKey="Negrotti A" first="A." last="Negrotti">A. Negrotti</name>
<affiliation wicri:level="1"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Istituto di Neurologia, Università di Parma, Parma</wicri:regionArea>
<wicri:noRegion>Parma</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Calzetti" sort="Calzetti" uniqKey="Calzetti" last="Calzetti">Calzetti</name>
<affiliation wicri:level="1"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Istituto di Neurologia, Università di Parma, Parma</wicri:regionArea>
<wicri:noRegion>Parma</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1997-01">1997-01</date>
<biblScope unit="vol">12</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="107">107</biblScope>
<biblScope unit="page" to="110">110</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">B76868CF03D01070A891C66A47A9A4CDFAF31704</idno>
<idno type="DOI">10.1002/mds.870120119</idno>
<idno type="ArticleID">MDS870120119</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antagonist</term>
<term>Antiallergic</term>
<term>Anticonvulsant</term>
<term>Antiemetic</term>
<term>Antihistaminic</term>
<term>Calcium Channel Blockers (administration & dosage)</term>
<term>Calcium Channel Blockers (adverse effects)</term>
<term>Calcium antagonist</term>
<term>Cardiovascular Diseases (drug therapy)</term>
<term>Cinnarizine</term>
<term>Cinnarizine (administration & dosage)</term>
<term>Cinnarizine (adverse effects)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug‐induced</term>
<term>Elderly</term>
<term>Female</term>
<term>Flunarizine</term>
<term>Flunarizine (administration & dosage)</term>
<term>Flunarizine (adverse effects)</term>
<term>Follow up study</term>
<term>Follow-Up Studies</term>
<term>H1 receptor</term>
<term>Humans</term>
<term>Long term</term>
<term>Long‐term outcome</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neurologic Examination (drug effects)</term>
<term>Parkinson Disease, Secondary (chemically induced)</term>
<term>Parkinson Disease, Secondary (diagnosis)</term>
<term>Parkinsonism</term>
<term>Piperazine derivatives</term>
<term>Prognosis</term>
<term>Toxicity</term>
<term>Treatment Outcome</term>
<term>Vasodilator agent</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Calcium Channel Blockers</term>
<term>Cinnarizine</term>
<term>Flunarizine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Calcium Channel Blockers</term>
<term>Cinnarizine</term>
<term>Flunarizine</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Cardiovascular Diseases</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Dose-Response Relationship, Drug</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antagoniste</term>
<term>Antagoniste calcium</term>
<term>Antiallergique</term>
<term>Anticonvulsivant</term>
<term>Antihistaminique</term>
<term>Antiémétique</term>
<term>Cinnarizine</term>
<term>Etude longitudinale</term>
<term>Flunarizine</term>
<term>Long terme</term>
<term>Parkinsonisme</term>
<term>Pipérazine dérivé</term>
<term>Pronostic</term>
<term>Récepteur histaminergique H1</term>
<term>Toxicité</term>
<term>Vasodilatateur</term>
<term>Vieillard</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The natural course of calcium‐entry blocker–induced parkinsonism was evaluated in 13 elderly patients previously exposed to cinnarizine or flunarizine or both for a median period of 7 months. Clinical assessments were carried out before drug discontinuation and twice thereafter over a period lasting ≤7 years. None of the patients showed a full recovery of extrapyramidal signs, indicating that the long‐term prognosis of the parkinsonism is less benign than previously reported. Two main patterns of clinical outcome were recognized (i.e., “remittent” and “persistent and not progressive”parkinsonism), whereas the development of a progressive disorder was observed only in one patient. No significant correlation was found between the patterns of outcome and some clinical variables, such as total duration of exposure to cinnarizine and flunarizine, cumulative drug dosages, and age at onset of parkinsonism. There was no significant difference in terms of family history of essential tremor or parkinsonism or both among the patients with the two main patterns of clinical course.</div>
</front>
</TEI>
<affiliations><list><country><li>Italie</li>
</country>
</list>
<tree><country name="Italie"><noRegion><name sortKey="Negrotti, A" sort="Negrotti, A" uniqKey="Negrotti A" first="A." last="Negrotti">A. Negrotti</name>
</noRegion>
<name sortKey="Calzetti" sort="Calzetti" uniqKey="Calzetti" last="Calzetti">Calzetti</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005425 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005425 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:B76868CF03D01070A891C66A47A9A4CDFAF31704 |texte= A long‐term follow‐up study of cinnarizine‐ and flunarizine‐induced parkinsonism }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |